Health
A novel monoclonal antibody therapy cuts LDL cholesterol by half in a high-risk patient population, – EurekAlert
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called ”bad” cholesterol–by 50 percent in patients with severe…
The investigational drug evinacumab reduced low-density lipoprotein (LDL) cholesterol–the so-called “bad” cholesterol–by 50 percent in patients with severe hypercholesterolemia whose condition is resistant to standard treatments, a phase 2 study from the Icahn School of Medicine of Mount Sinai and other global academic sites has found. Results from the study sponsored by Regeneron, are being presented as “late breaking science” at the American Heart Association Scientific Sessions 2020 on Sunday,…
-
Noosa News22 hours agoEnsure voices are heard – Proctor
-
General24 hours agoFederal politics live: Government says RBA rate cut decision about ‘pace, not direction’
-
General24 hours agoReserve Bank board still looking for yesterday’s news
-
Business23 hours agoASX ETFs to target amidst an ageing population